Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies. The company develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-na?ve and TKI-pretreated patients. The company's main drug candidate is repotrectinib (TPX-0005). In addition to repotrectinib, the company's pipeline includes two clinical-stage multi-targeted kinase inhibitors, TPX-0022 (a MET/CSF1R/SRC inhibitor) and TPX-0046 (a RET/SRC inhibitor), and a preclinical ALK inhibitor, TPX-0131, which is entering IND-enabling studies. The company's fourth drug candidate, TPX-0131 is a preclinical ALK inhibitor.
  • TickerTPTX
  • ISINUS90041T1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
TPTX Turning Point T... (Health Care)

TURNING POINT THERAPEUTICS sees an upgrade to Neutral thanks to a bett...

The independent financial analyst theScreener just awarded an improved star rating to TURNING POINT THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 71.50 and its target price was estimated at USD 55.12.

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual...

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9. Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. ET and will be accessible via audio webcast through the I...

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice Pr...

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business de...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Reports First-Quarter Financial Results, Pr...

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 Investigational New Drug Application Cleared for Combination of Repotrectinib and MEK-inhibitor Trametinib in KRAS-Driven Tumors; TRIDENT-2 Study on Track to Initiate Mid-YearTPX-0022 SHIELD-1 Study Progressing Toward Recommended Phase 2 DoseTPX-0131 Phase 1/2 FORGE-1 Study InitiatedCash, Cash Equivale...

TPTX Turning Point T... (Health Care)

TURNING POINT THERAPEUTICS sees an upgrade to Neutral thanks to a bett...

The independent financial analyst theScreener just awarded an improved star rating to TURNING POINT THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 71.50 and its target price was estimated at USD 55.12.

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual...

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9. Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. ET and will be accessible via audio webcast through the I...

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice Pr...

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business de...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Reports First-Quarter Financial Results, Pr...

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 Investigational New Drug Application Cleared for Combination of Repotrectinib and MEK-inhibitor Trametinib in KRAS-Driven Tumors; TRIDENT-2 Study on Track to Initiate Mid-YearTPX-0022 SHIELD-1 Study Progressing Toward Recommended Phase 2 DoseTPX-0131 Phase 1/2 FORGE-1 Study InitiatedCash, Cash Equivale...

TPTX Turning Point T... (Health Care)

TURNING POINT THERAPEUTICS sees an upgrade to Neutral thanks to a bett...

The independent financial analyst theScreener just awarded an improved star rating to TURNING POINT THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 71.50 and its target price was estimated at USD 55.12.

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual...

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9. Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. ET and will be accessible via audio webcast through the I...

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice Pr...

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business de...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Reports First-Quarter Financial Results, Pr...

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 Investigational New Drug Application Cleared for Combination of Repotrectinib and MEK-inhibitor Trametinib in KRAS-Driven Tumors; TRIDENT-2 Study on Track to Initiate Mid-YearTPX-0022 SHIELD-1 Study Progressing Toward Recommended Phase 2 DoseTPX-0131 Phase 1/2 FORGE-1 Study InitiatedCash, Cash Equivale...

TPTX Turning Point T... (Health Care)

TURNING POINT THERAPEUTICS sees an upgrade to Neutral thanks to a bett...

The independent financial analyst theScreener just awarded an improved star rating to TURNING POINT THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 71.50 and its target price was estimated at USD 55.12.

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual...

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9. Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. ET and will be accessible via audio webcast through the I...

 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice Pr...

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business de...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
TPTX Turning Point T... (Health Care)

Turning Point Therapeutics Reports First-Quarter Financial Results, Pr...

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 Investigational New Drug Application Cleared for Combination of Repotrectinib and MEK-inhibitor Trametinib in KRAS-Driven Tumors; TRIDENT-2 Study on Track to Initiate Mid-YearTPX-0022 SHIELD-1 Study Progressing Toward Recommended Phase 2 DoseTPX-0131 Phase 1/2 FORGE-1 Study InitiatedCash, Cash Equivale...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch